How much research do you have to support your results?

All of our products are thoroughly validated in-house using clinical outcomes data and we have published multiple peer-reviewed papers demonstrating the efficacy of our predictions (Veterinary Sciences and Veterinary and Comparative Oncology). We have run over 12,000 tests on hematopoietic cells, and over 4,000 canine patients that have benefited from our services. We believe we have more data on canine lymphoma than any other company in the world.

Other Questions

Back to Help Center

Would we need to set up a Vet Portal for each doctor or just our hospital?

If you would like to set up accounts for the hospital, please send us a list of doctors' names and email addresses as well as any support staff who would need access to the Vet Portal. Each doctor can also register independently on the Vet Portal. Please note the report will be sent to the ordering veterinarian's email, not to all hospital accounts.

Read More

Do you test "rescue" drugs as well?

Yes, many of the 13 anticancer drugs we provide predictions for are used for rescue therapy. The drugs we test against are: L-Asparaginase, Mitoxantrone, Vincristine, Vinblastine, Doxorubicin, Tanovea, Chlorambucil, Mechlorethamine, Lomustine, Prednisone, Cyclophosphamide, Melphalan, and Dexamethasone.

Read More

For patients who already have flow cytometry, can you just run the drug sensitivity profile?

No, we cannot run a drug sensitivity-only service. Please understand our AI-based drug response prediction models require flow cytometry and PARR parameters generated from our own instrumental setting. Even if the patient already has flow cytometry results from another laboratory, we need to run flow and PARR again anyway.

Read More

Can we select non-MDR substrate drugs for known or suspected MDR dogs?

Yes, you can select non-MDR1 drugs when indicating your drug priorities, but the final report will also include all drugs.

Read More

What does PARR tell me about my patient’s specimen?

PARR, which stands for PCR for Antigen Receptor Rearrangements, is used to discriminate between lymphoma/leukemia and reactive/inflammatory conditions when cytology is equivocal. Our canine PARR assay detects the expansion of B-cell cancer clones by amplifying the VJ region of the immunoglobulin heavy chain gene (IgH) and detects the expansion of T-cell cancer clones by amplifying a region in the T-cell receptor gamma chain gene.

Read More